|
ncRNAs species | | Cancer type | Biological function | Mechanism | Refs |
|
miRNA | miR-9 | melanoma | promote migration and angiogenesis | target to SOCS5 and activating JAK-STAT signaling pathway | [24] |
| miR-16, miR-21, miR-29a | lung cancer | promote tumor growth and metastasis | bind with TLR, trigger TLR-mediated pro-metastatic inflammatory response | [30] |
| miR-92a | leukemia | regulate endothelial gene expression | Downregulate target gene integrin a5, play a similar role in endogenous miRNAs in HUVECs | [19] |
| miR-100-5p, miR-21-5p, miR-139-5p | prostate cancer | modify pre-metastatic niche | increase MMP2, 9, 13, RANKL and fibroblast migration | [29] |
| miR-105 | breast cancer | promote metastasis | destroy the vascular barriers by downregulating ZO-1 | [21] |
| miR-122 | breast cancer | induce angiogenesis | downregulate the glucose metabolism by decreasing PKM and GLUT1 | [26] |
| miR-135b | multiple myeloma | enhance endothelial tube formation under hypoxia | suppress FIH-1 in endothelial cells via the HIF-FIH signaling pathway | [20] |
| miR-181c | brain-metastatic breast cancer | facilitate migration | downregulate PDPK1 in brain endothelial cells to trigger BBB destruction | [22] |
| miR-210 | leukemia | affect angiogenesis | exosomes containing a high expression level of miR-210 downregulate EFNA3 | [25] |
| miR-494, miR-542-3p | pancreatic adenocarcinoma | accelerate the pre-metastatic niche formation | target cdh-17 and over express MMP2 and MMP3 | [28] |
lncRNA | H19 | hepatocellular carcinoma | promote angiogenesis and intercellular adhesion | up-regulate the VEGF, promote MMP9, CXCL12, and the recruitment of BMDCs | [35–37] |
| LncRNA Sox2ot | Pancreatic duct adenocarcinoma | promote the invasion and metastasis | regulate Sox2 expression by binding the miR-200 family competitively | [38] |
| lncRNA MALAT1, linc-ROR | anaplastic thyroid carcinoma | establish pre-metastatic niche | induce EMT | [39] |
|